Overview
Dr. Latania Logan is a Professor of Pediatrics, Marcus Professor of Pediatric Infectious Diseases in the Department of Pediatrics at Emory University. She is a nationally recognized physician-scientist whose research focuses on the clinical and molecular epidemiology of multidrug-resistant gram-negative bacterial infections, particularly among children, young adults, and community reservoirs.
Dr. Logan earned her undergraduate degree from the University of Michigan, her MD from Wayne State University, and her MSPH from the University of Illinois at Chicago. She completed her residency in pediatrics and fellowship in pediatric infectious diseases at Northwestern University Feinberg School of Medicine and Ann & Robert H. Lurie Children’s Hospital of Chicago.
She began her academic career at Rush University Medical Center in Chicago, where she held several leadership roles including Chief of Pediatric Infectious Diseases, Vice Chair of Pediatric Research, Pediatric Hospital Epidemiologist, and Professor of Pediatrics at Rush Medical College. In August 2022, she joined Emory University School of Medicine and the Children’s Healthcare of Atlanta.
Dr. Logan’s translational research laboratory applies a One Health approach to investigate the environmental and community origins of multidrug-resistant Enterobacterales and their impact on antimicrobial resistance. Her work integrates clinical and genomic epidemiology, microbiology, molecular, and patient and population level data to track transmission pathways and inform public health interventions. These efforts aim to bridge the gap between clinical (human and animal) medicine, public health, genomics, epidemiology, and environmental microbiology to support the development of sustainable, community-based infection prevention strategies.
Her research is supported by the National Institutes of Health (NIH) and the Environmental Protection Agency (EPA), including studies that advance the understanding of antimicrobial resistance, One Health, and its broader public health implications to children, healthy persons and the community.
In addition to her research, Dr. Logan plays a prominent role in national infectious disease efforts. She is an active member of the NIH-funded Antibacterial Resistance Leadership Group (ARLG), serving on both the Gram-Negative and Pediatric Committees, a speaker and member of the National Academy of Medicine Emerging Leaders in 2023 and 2025, and currently serves as an expert panel member on a WHO Antimicrobial Resistance program development task force. She also serves as a Chair for IDWeek 2025 and as the Pediatrician on the CDC funded Chicago Prevention and Intervention Epicenter, which focuses on controlling and preventing healthcare-associated infections.
Our Focus
Dr. Latania Logan’s laboratory is dedicated to the clinical and molecular epidemiology of multidrug-resistant (MDR) gram-negative bacterial infections, particularly among children and healthy populations. A central focus is on Enterobacterales, a group of bacteria increasingly responsible for drug-resistant infections in both hospital and community settings.
Despite extensive efforts in antibiotic stewardship and infection prevention in healthcare environments, these infections continue to rise. Dr. Logan’s lab investigates the community reservoirs of MDR Enterobacterales to better understand how these organisms persist and spread outside of hospitals. Dr. Logan’s translational research laboratory uses a One Health approach to understand, identify, and characterize community reservoirs and environmental origins of multidrug-resistant Enterobacterales, as infections with these organisms have continued to increase despite aggressive antibiotic stewardship and infection prevention campaigns in healthcare settings.Through clinical studies, molecular surveillance, and epidemiologic research, the lab aims to uncover transmission pathways and develop targeted strategies for prevention.
Our Mission
To expand scientific understanding of how drug-resistant infections develop and spread, especially in vulnerable pediatric populations—ultimately leading to better treatment and prevention approaches.